Lataa...
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
The selection of colorectal cancer patients for anti-epidermal growth factor receptor (EGFR) antibody therapy is based on the determination of their RAS mutation status—a strongly negative predictive factor—since the protein target, EGFR, is not a reliable predictor of therapeutic response. In this...
Tallennettuna:
| Julkaisussa: | Cancers (Basel) |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7139947/ https://ncbi.nlm.nih.gov/pubmed/32155907 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030614 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|